新天药业(002873) - 2022 Q3 - 季度财报

Financial Performance - The company's revenue for Q3 2022 reached ¥344,696,330.89, representing an increase of 18.36% compared to the same period last year[5]. - Net profit attributable to shareholders was ¥47,439,961.79, up 12.69% year-on-year, while the net profit excluding non-recurring gains and losses was ¥46,140,566.11, an increase of 16.56%[5]. - The net profit for the third quarter of 2022 was CNY 104,887,601.16, an increase of 18% compared to CNY 88,933,462.49 in the same period last year[20]. - Operating income for the third quarter reached CNY 116,780,742.51, up from CNY 101,463,975.16, reflecting a growth of approximately 15.5% year-over-year[19]. - The total revenue from sales of goods and services was CNY 823,211,488.02, up from CNY 730,647,546.59, indicating a growth of approximately 12.6%[22]. Earnings Per Share - The basic earnings per share (EPS) for the period was ¥0.2863, reflecting an 8.53% increase year-on-year, while diluted EPS was ¥0.2672, up 7.14%[5]. - The basic earnings per share increased to CNY 0.6332 from CNY 0.5519, representing a growth of about 14.7%[20]. Assets and Liabilities - Total assets at the end of the reporting period amounted to ¥1,644,701,803.91, a 7.89% increase from the end of the previous year[5]. - As of September 30, 2022, total assets were CNY 1,644,701,803.91, up from CNY 1,524,426,501.68 at the beginning of the year, indicating a growth of 7.9%[17]. - The total liabilities as of September 30, 2022, were CNY 634,030,033.19, slightly up from CNY 633,983,091.90 at the beginning of the year[17]. - The company's equity attributable to shareholders reached CNY 1,010,671,770.72, an increase from CNY 890,443,409.78, reflecting a growth of 13.5%[17]. Cash Flow - The company's cash flow from operating activities for the year-to-date was ¥62,907,793.14, showing a decrease of 35.60% compared to the previous year[10]. - The cash flow from operating activities generated a net amount of CNY 62,907,793.14, down from CNY 97,683,353.15, a decrease of about 35.5%[23]. - The company reported a cash and cash equivalents balance of CNY 89,909,959.56 at the end of the period, compared to CNY 98,284,359.97 at the end of the previous year, reflecting a decrease of approximately 4.5%[24]. Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 22,434[12]. - The largest shareholder, Guiyang Xintian Biotechnology Development Co., Ltd., holds 34.56% of the shares, with 33,821,441 shares pledged[12]. Borrowings and Investments - The company reported a significant increase in long-term borrowings, which rose by 399.37% to ¥25,000,000.00, attributed to new borrowings during the period[10]. - The short-term borrowings decreased to CNY 257,000,000.00 from CNY 268,342,558.34, a reduction of 4.9%[17]. - The company experienced a net cash outflow from investing activities of CNY 24,225,800.33, an improvement from a net outflow of CNY 198,550,274.06 in the previous year[23]. - The financing activities resulted in a net cash outflow of CNY 21,250,130.68, compared to a net outflow of CNY 130,936,122.11 in the same period last year[23]. Operating Costs and Expenses - The total operating revenue for the third quarter of 2022 reached CNY 869,234,233.67, an increase of 16.6% compared to CNY 745,264,628.80 in the same period last year[18]. - The total operating costs for the same period amounted to CNY 749,807,302.84, reflecting a rise of 16.3% from CNY 644,773,028.12 year-on-year[18]. - The total operating expenses rose to CNY 428,144,471.00, compared to CNY 366,976,813.99, an increase of approximately 16.6%[19]. - Research and development expenses increased to CNY 12,571,577.53, compared to CNY 11,714,744.33, marking a rise of about 7.3%[19]. Government Subsidies - The company received government subsidies amounting to ¥1,724,872.07 during the reporting period, contributing to its financial performance[7].